Heron Therapeutics
Logotype for Heron Therapeutics Inc

Heron Therapeutics (HRTX) investor relations material

Heron Therapeutics Q2 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Heron Therapeutics Inc
Q2 2026 earnings summary10 Aug, 2026

Executive summary

  • Q2 2026 net revenue was $37.7 million, up 9% sequentially but flat year-over-year and slightly below expectations.

  • Acute care franchise revenue grew 43.9% year-over-year, driven by ZYNRELEF (up 35%) and APONVIE (up 74%), while oncology franchise revenue declined 15.9% year-over-year due to competition.

  • Net loss widened to $5.5 million in Q2 2026 from $2.4 million in Q2 2025.

  • SUSTOL continues its planned wind down and will be withdrawn from the market as of September 30, 2026.

  • Strategic alternatives are under review, with spending tightened and sales force expansion paused following recent legal developments.

Financial highlights

  • Gross margin for Q2 2026 was 69.3%, down from 73.5% in Q2 2025.

  • R&D expense was $2.7 million; SG&A expense was $25.4 million; total operating expenses were $28.1 million.

  • Adjusted EBITDA was $3.2 million, up from $2.2 million year-over-year.

  • Cash and short-term investments at quarter-end were $42.7 million.

  • Cost of product sales rose 17.4% in Q2, reflecting higher inventory reserves and increased units sold.

Outlook and guidance

  • Full-year 2026 guidance for net product sales and adjusted EBITDA was withdrawn due to uncertainty from a June court decision and potential generic competition.

  • Management expects cash resources to cover at least one year of operations, but this is based on assumptions that could change.

  • Will report cash position, spending, and covenant compliance quarterly instead of annual guidance.

  • Strategic alternatives are being considered, with no assurance of a transaction or favorable terms.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Heron Therapeutics earnings date

Logotype for Heron Therapeutics Inc
Q3 20269 Nov, 2026
Heron Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Heron Therapeutics earnings date

Logotype for Heron Therapeutics Inc
Q3 20269 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Heron Therapeutics Inc. is a biotechnology company focused on developing and commercializing therapies to address unmet medical needs in acute care and oncology. The company specializes in creating treatments for pain management and chemotherapy-induced side effects, such as nausea and vomiting. Heron Therapeutics utilizes its proprietary technology platforms to develop extended-release therapies that aim to improve patient comfort and treatment outcomes. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.